Skip to contentC
Cumberland Pharmaceuticals Inc
C
CPIXCumberland Pharmaceuticals Inc Q1 2018 · 10-Q
Revenue$8.59M$8.59M−10.9% vs Q1 2017 Net Income-$2.38M-$2.38MN/M vs Q1 2017 EPS Diluted-$0.15-$0.15N/M vs Q1 2017 Operating Income-$2,452,222N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cumberland Pharmaceuticals Inc · CIK 1087294 · Engraved from SEC EDGAR
Free Cash Flowderived$140,708−89.3% Margins · derivedOperating margin-28.6%−21.7 pt vs Q1 2017
Net margin-27.7%−14.5 pt vs Q1 2017
ended Mar 31, 2018 · filed May 9, 2018 · 39 d after period end